Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • China sharply rebukes US over decision to shoot down spy balloon
    • Antony Blinken cancels China trip following discovery of spy balloon
    • How much of a threat are Chinese spy balloons?
    • Nigeria’s attempt to replace its currency notes descends into chaos
    • EU agrees price caps on Russian oil products
  • UK
    Sections
    • UK Home
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • Middle-class Britons are the ‘new vulnerable’, says Tyrie
    • Cost of fixed-rate mortgages set to fall as UK inflation outlook brightens
    • Sunak under pressure from growing Raab row and critical ex-PMs
    • Ofgem ‘asleep at the wheel’ while suppliers fitted prepayment meters
    • NHS staff in Wales call off strike after Cardiff boosts pay offer
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Indian authorities seek to calm investors after Adani sell-off
    • Swiss authorities open criminal probe into bank data breaches
    • TotalEnergies says exposure to Adani stands at $3.1bn as turmoil mounts
    • Australian battery group selected as preferred bidder for Britishvolt
    • EY under fire over its two roles at battery start-up Britishvolt
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Hedge funds rush to unwind bets on falling markets as stocks surge
    • Middle-class Britons are the ‘new vulnerable’, says Tyrie
    • Indian authorities seek to calm investors after Adani sell-off
    • Nigeria’s attempt to replace its currency notes descends into chaos
    • EU agrees price caps on Russian oil products
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The worst airport in the world
    • Tempting back older workers means ditching business as usual
    • Toyota has a tragic flaw in the electric vehicle drama
    • Marie Kondo’s epiphany proves there is no magic in clinical tidiness
    • Britain should not accept its status as the ‘sick man of Europe’
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Barclays chief: the life lessons I have discovered during cancer treatment
    • Shoshana Zuboff: ‘Privacy has been extinguished. It is now a zombie’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • After hours with 10 Foot, London’s most notorious graffiti writer
    • Meet the man quietly revolutionising publishing
    • Germany grapples with the limits of pacifism
    • Rugby superstar Siya Kolisi: ‘I’ve got no ego at all’
    • My downshift to deepest Spain
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Coronavirus treatment

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Sunday, 29 January, 2023
    Drugs research
    RQ Bio partners with AstraZeneca in Covid antibody fight

    UK biotech racing to keep antibody up to date with latest variants

  • Thursday, 26 January, 2023
    UK universities
    Lack of clinical academics threatens NHS research and teaching, say peers

    Shortage of doctors with university posts is putting health service on ‘dangerous precipice’

  • Tuesday, 24 January, 2023
    Kate Bingham
    Britain is losing its chance to become a life sciences superpower

    Short-termism and suspicion in parts of government risk our valuable future in precision medicine

  • Monday, 23 January, 2023
    News in-depth
    Rural China runs short of Covid drugs over lunar new year holiday

    Officials row with Pfizer over price as villages struggle to obtain antiviral medication

  • Friday, 13 January, 2023
    Wes Streeting
    Only radical thinking can find a long-term cure for the NHS

    Starting with primary care, investment combined with modernisation can deliver better outcomes for patients

  • Thursday, 12 January, 2023
    EU economy
    EU draws up plans to stockpile scarce medicines

    Effort to improve health supply chain issues that have led to Greece imposing an export ban on drugs

  • Tuesday, 10 January, 2023
    Covid-19 vaccines
    Chinese bank tries to entice wealthy customers with mRNA vaccines

    Hong Kong-based lender seeks to cater to mainlanders’ demand for western jabs

  • Tuesday, 10 January, 2023
    Coronavirus pandemic
    China’s Covid patients face medical debt crisis as insurers refuse coverage

    Narrow definition of cases leaves claimants on the hook after state-backed policies drop free care

  • Monday, 9 January, 2023
    CureVac GmbH
    Covid vaccine makers CureVac and Novavax appoint new chiefs

    Pharmaceutical groups to part ways with longstanding executives

  • Monday, 9 January, 2023
    InterviewPharmaceuticals sector
    SK Bioscience says ‘national pride’ prevents China from accepting foreign Covid jabs

    South Korean vaccine maker looks elsewhere to expand overseas business

  • Friday, 6 January, 2023
    Pharmaceuticals sector
    US approves Alzheimer’s drug that slows rate of cognitive decline

    High price of treatment and restrictions on medicine developed by Eisai and Biogen will limit patient access initially

  • Friday, 6 January, 2023
    Covid-19 vaccines
    New Chinese mRNA Covid vaccine shows positive early results

    Jab developed by CanSinoBio could help nation grappling with a wave of infection

  • Friday, 6 January, 2023
    Coronavirus economic impact
    Ambulances left waiting for record times as ‘twindemic’ hits UK

    Covid and flu hospitalisations soar over Christmas as emergency service delays worsen

  • Thursday, 5 January, 2023
    ExplainerCoronavirus pandemic
    How serious is the threat of new Covid-19 variants?

    A surge in cases after China lifted restrictions has sparked concerns that a dangerous new strain could emerge

  • Tuesday, 3 January, 2023
    Covid-19 vaccines
    EU offers free Covid-19 vaccines to China to help curb outbreak

    Beijing rejects Brussels’ offer, citing full control of situation

  • Wednesday, 28 December, 2022
    China’s elite give Paxlovid to friends as demand soars for Covid drug

    Pfizer’s antiviral ‘more coveted than Moutai’ as authorities restrict imports despite virus wave

  • Tuesday, 27 December, 2022
    News in-depthCoronavirus pandemic
    ‘Made of flesh, not iron’: China’s medics battle zero-Covid exit wave

    Doctors and nurses given ‘no choice’ but to work while infected after influx of cases inundates hospitals

  • Monday, 26 December, 2022
    Chinese society
    Chinese vaccine tourists flock to Macau for mRNA Covid jabs

    Explosion of cases and ban on more effective western shots lead residents to look abroad

  • Friday, 23 December, 2022
    LexDrugs research
    Medicines: triumph of science in 2022 is worth celebrating Premium content

    From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances

  • Thursday, 22 December, 2022
    Merck antiviral trial shows promising impact on Covid recovery time

    Results of UK study show drug cuts symptom duration by about 4 days but does not reduce deaths

  • Thursday, 22 December, 2022
    Chinese business & finance
    China tells factories to prioritise government Covid orders

    Companies report local officials are monitoring production lines to speed up supplies

  • Friday, 16 December, 2022
    UK labour disputes
    Strike by ambulance workers to cause ‘extensive disruption’

    NHS boss presses health managers to take steps to cope with the walk out by paramedics

  • Monday, 12 December, 2022
    Covid-19 vaccines
    China warned to accelerate approval of updated jabs to tackle Covid ‘tsunami’

    Authorities have relied on vaccines made using original strain found in Wuhan

  • Wednesday, 7 December, 2022
    Coronavirus pandemic
    China risks ‘wave of infections’ after relaxing zero-Covid policy, warns Fauci

    Joe Biden’s chief medical adviser urges Beijing to approve use of western vaccines

  • Tuesday, 6 December, 2022
    News in-depthChinese politics & policy
    China’s elderly vaccine refuseniks pose obstacle for Xi Jinping

    Nearly 90mn Chinese are insufficiently protected against Covid as Beijing begins to unwind pandemic controls

Previous page You are on page 1 Next page

Recommended

Covid-19 vaccines
Covid-19 vaccine tracker: Lowest-income countries lag further behind rest of the world
Covid-19 vaccines
Covid vaccine development: The shots available and the doses administered
Covid-19 vaccines
In graphics: the UK vaccine supply chain
Coronavirus: free to read
Coronavirus tracker: the latest figures as countries fight the Covid-19 resurgence

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In